Spero Therapeutics, Inc.SPRONASDAQ
Loading
EBITDA as a percentage of revenue
Percentile
P70
Within normal range
vs 2Y Ago
-4.8x
Contraction
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | -126.22% | +16.5% |
| 2024 | -151.08% | -677.4% |
| 2023 | 26.16% | +129.6% |
| 2022 | -88.39% | +96.9% |
| 2021 | -2839.41% | -238.1% |
| 2020 | -839.79% | -144.0% |
| 2019 | -344.22% | +67.8% |
| 2018 | -1069.01% | +48.9% |
| 2017 | -2090.30% | +78.7% |
| 2016 | -9833.43% | - |